Patent intelligence · US
US 11332500
Heterotandem bicyclic peptide complexes
Heterotandem bicyclic peptide complexes
Patent details — US 11332500
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 17, 2022
- Expiration
- May 12, 2042
- Applicant
- BicycleTx Limited
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61K47/543, A61K47/545
Quick answer
US 11332500 (Heterotandem bicyclic peptide complexes) is held by BicycleTx Limited. Status: granted. Granted May 17, 2022. Expires May 12, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BicycleTx Limited
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K38/00, A61K47/543, A61K47/545, A61K47/60, A61K47/64
More from BicycleTx Limited
Related pharmaceutical patents in our USPTO index.
-
US 12378288
Multimeric bicyclic peptide ligands
granted -
US 12377155
Bicyclic peptide ligands specific for PSMA
granted -
US 12350343
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 12049520
Bicyclic peptide ligands specific for CD137
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11970553
Heterotandem bicyclic peptide complex
granted
Frequently asked questions
What is US patent 11332500?
US 11332500 (Heterotandem bicyclic peptide complexes) is held by BicycleTx Limited. Status: granted. Granted May 17, 2022. Expires May 12, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11332500?
BicycleTx Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 11332500 expire?
Our index shows an expiration date of May 12, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.